Market Cap | 3.61B | P/E | 22.48 | EPS this Y | -0.80% | Ern Qtrly Grth | 46.30% |
Income | 197.92M | Forward P/E | 14.23 | EPS next Y | 5.90% | 50D Avg Chg | 13.00% |
Sales | 492.05M | PEG | 2.68 | EPS past 5Y | 41.74% | 200D Avg Chg | 22.00% |
Dividend | N/A | Price/Book | 5.43 | EPS next 5Y | 3.10% | 52W High Chg | -10.00% |
Recommedations | 2.20 | Quick Ratio | 12.24 | Shares Outstanding | 84.26M | 52W Low Chg | 66.00% |
Insider Own | 9.77% | ROA | 16.22% | Shares Float | 75.66M | Beta | 2.17 |
Inst Own | 68.57% | ROE | 29.50% | Shares Shorted/Prior | 6.09M/6.78M | Price | 43.39 |
Gross Margin | 83.60% | Profit Margin | 40.22% | Avg. Volume | 1,522,459 | Target Price | 28.40 |
Oper. Margin | 40.42% | Earnings Date | Apr 30 | Volume | 1,248,768 | Change | -1.03% |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Barclays | Overweight | Feb 15, 24 |
UBS | Neutral | Feb 14, 24 |
Barclays | Overweight | Jan 18, 24 |
Barclays | Overweight | Jan 4, 24 |
Canaccord Genuity | Hold | Dec 7, 23 |
UBS | Neutral | Nov 3, 23 |
Canaccord Genuity | Hold | Oct 13, 23 |
Barclays | Overweight | Aug 1, 23 |
Canaccord Genuity | Buy | Jul 28, 23 |